Keep Regulatory Status Quo Post-Brexit, Industry Tells Negotiators
Executive Summary
The future regulatory outlook for the UK after the country leaves the EU has not been clear during discussions to date. Now medtech industry associations have spoken out. They warn divergence will hit patient safety and must be avoided.
You may also be interested in...
UK Begins Brexit Inquiry On Devices, Pharma Supplies
In a busy week for Brexit watchers, the UK government has initiated an inquiry into the effects of future regulatory systems that will potentially impact medical technology and other health-care products in the UK after the country has left the EU.
EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency
Notified bodies have been a pivotal part of the EU medtech regulatory system since it was first launched in the 1990s. Where might they fit within a new medtech regulatory governance structure? Panelists on a recent vodcast grappled with the question.
First Public Discussion On How EU Medtech Regulatory Governance Structure May Evolve
Does the EU need a medtech agency for the first time in its history? Nothing can or should be decided too quickly but five high-profile experts broadly agreed that change is now critical.